4//SEC Filing
Barrett Elizabeth A. 4
Accession 0001437749-23-002358
CIK 0001668243other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 3:40 PM ET
Size
17.2 KB
Accession
0001437749-23-002358
Insider Transaction Report
Form 4
Barrett Elizabeth A.
Chief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-01-31−13,333→ 13,334 total→ Ordinary Shares (13,333 underlying) - Award
Restricted Stock Units
2023-01-31+75,000→ 75,000 total→ Ordinary Shares (75,000 underlying) - Exercise/Conversion
Ordinary Shares
2023-01-31+13,333→ 326,691 total - Exercise/Conversion
Restricted Stock Units
2023-01-31−5,000→ 0 total→ Ordinary Shares (5,000 underlying) - Award
Performance Stock Units
2023-01-31+100,000→ 100,000 total→ Ordinary Shares (100,000 underlying) - Award
Employee Stock Option (right to buy)
2023-01-31+125,000→ 125,000 totalExercise: $10.39Exp: 2033-01-31→ Ordinary Shares (125,000 underlying) - Exercise/Conversion
Ordinary Shares
2023-01-31+5,000→ 313,358 total
Footnotes (8)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F2]The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021.
- [F3]The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022.
- [F4]1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
- [F5]1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
- [F6]Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F7]All shares underlying the performance stock units will vest upon achievement of a corporate milestone event.
- [F8]The performance stock units were approved by the Board of Directors of the Issuer on January 31, 2023. If the performance stock units are not ratified by the Issuer's shareholders at the Issuer's 2023 annual general meeting, the performance stock units will terminate.
Documents
Issuer
UroGen Pharma Ltd.
CIK 0001668243
Entity typeother
Related Parties
1- filerCIK 0001764157
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 3:40 PM ET
- Size
- 17.2 KB